ReviewBiomolecules2026
Understanding Tryptase Physiology, Clinical Significance, and Diagnostic Applications: Where Do We Stand?
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tryptase is the principal biomarker of mast cell (MC) burden and activation, routinely used in the diagnosis and management of MC-related disorders. Beyond its established role in confirming anaphylaxis, serum tryptase has gained increasing relevance in the diagnosis of systemic mastocytosis, hereditary α-tryptasemia (HαT), cutaneous mastocytosis, and selected haematologic diseases. Recent advances in MC biology, tryptase genetics, and disease classification have substantially improved the interpretation of baseline and acute (event-related) tryptase measurements. In particular, validation of the "20% + 2" consensus formula for MC activation and the recognition of HαT as a common genetic cause of elevated baseline serum tryptase have refined diagnostic algorithms and risk-stratification strategies. This review summarizes current knowledge on tryptase physiology, laboratory assessment, and clinical significance across multiple disease settings, with particular emphasis on the interpretation of baseline serum tryptase, the diagnostic role of tryptase in anaphylaxis and mastocytosis, and emerging applications in allergy, hematology, and chronic inflammatory disorders. Understanding both the strengths and limitations of serum tryptase measurement is essential for accurate diagnosis, prognostic assessment, and personalized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.